Partnership Between Premier's ProvideGx Program and Exela Pharma Sciences Successfully Resolves National Shortage of Cysteine Hydrochloride
October 08, 2019
October 08, 2019
CHARLOTTE, North Carolina, Oct. 8 -- Premier, a healthcare improvement company, issued the following news release:
Premier Inc. (NASDAQ: PINC), through its ProvideGx(TM) program, and Exela Pharma Sciences, LLC, have successfully resolved the multi-year, national shortage of cysteine hydrochloride injection.
Cysteine hydrochloride, a critical drug for pediatric and adult patients who require parenteral nutrition (PN), was officially delisted from the U.S. Food and Drug A . . .
Premier Inc. (NASDAQ: PINC), through its ProvideGx(TM) program, and Exela Pharma Sciences, LLC, have successfully resolved the multi-year, national shortage of cysteine hydrochloride injection.
Cysteine hydrochloride, a critical drug for pediatric and adult patients who require parenteral nutrition (PN), was officially delisted from the U.S. Food and Drug A . . .